Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents as inhibitors of phosphodiesterase 5 cardiovascular disorders ##STR00001##

5-Aryl isoxazole derivatives of general formula (I): ##STR1## wherein: Ar represents phenyl optionally substituted substituted by one or more groups R.sup.2 or pyridyl substituted by one or more groups R.sup.2 ; R represents: hydrogen, --CO.sub.2 R.sup.3, --COR.sup.4, cyano, halogen, alkyl or haloalkyl; R.sup.1 represents: alkyl, haloalkyl or cycloalkyl; R.sup.2 represents: a halogen atom, R.sup.4, nitro, --CO.sub.2 R.sup.3, --OR.sup.4, --S(O).sub.m R.sup.4, --S(O).sub.m R.sup.5, --O--(CH.sub.2)...

The invention concerns a cyclic ether derivative of the formula I ##STR1## wherein Ar.sup.1 is optionally substituted phenyl, naphthyl or a 9- or 10-membered bicyclic heterocyclic moiety; A.sup.1 is a direct link to X.sup.1 or (1-3C)alkylene; X.sup.1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar.sup.2 is optionally substituted phenylene or pyridylene; R.sup.1 includes hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl and (1-4C)alkylthio; and R.sup.2 and R.sup.3 together form a group of the formula -...

The present invention relates to compounds ##STR1## where G is ##STR2## and Z is oxygen or sulfur and the remaining variables are as defined in the Specification. The compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

A photographic material is disclosed comprising a support, at least one silver halide emulsion layer, and optionally one or more non-photosensitive hydrophylic layer(s), characterized in that at least one of said emulsion layer(s) and/or non-photosensitive layer(s) contains a triphenylmethane dye, absorbing around 670 nm, represented by general formula (ID) : ##STR1## wherein R.sup.1 and R.sup.2 each independently represents hydrogen unsubstituted or substituted alkyl, or unsubstituted or substi...

Novel crystal forms of the fluoroquinolone, [S-(R*,S*)]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylam ino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid are disclosed. The forms are characterized by one methanol solvate form, and three anhydrous polymorphic forms, of which, Form III exhibits greatest stability and decreased hygroscopicity.

This invention relates to compounds with strong affinity for NK.sub.1 receptor and useful for preparing drugs for treating substance P-dependent pathological conditions having the formula ##STR1## in which: m is two or three; n is 0; Am is a group ##STR2## R.sub.2 is a phenyl which is unsubstituted or monosubstituted or polysubstituted by a halogen atom, a hydroxyl, a (C.sub.1 -C.sub.4)-alkoxy, a (C.sub.1 -C.sub.4)-alkyl or a trifluoromethyl, said substituents being identical or different; X is ...

A compound which inhibits human thrombin and which has the general structure ##STR1##

"Novel compounds, such as: ##STR1## are disclosed. Also disclosed are methods for inhibiting the abnormal growth of cells, for inhibiting farnesyl protein transferase and for treating cancers using the novel compounds."

The present invention relates to compound LK6-A represented by the formula: ##STR1## which has immunosuppressive activity, and pharmaceutically acceptable salts thereof.